Pharmaseal and Viedoc have entered into a technology integration partnership designed to improve the management of clinical trials.
By combining Pharmaseal's advanced clinical trial management system (CTMS) platform with Viedoc's electronic data capture (EDC) and e-clinical technologies, the companies will create an integrated, cloud-based solution.
According to the companies, the platform will simplify trial oversight, accelerate study timelines and improve data quality, while ensuring regulatory compliance and operational efficiency.
The new Engility trial management platform is designed specifically to help manage the complexity of global studies, who empowering sponsors and contract research organisations (CROs) to optimise their clinical operations.
By integrating Viedocs' EDC technology, the companies offer a platform that provides seamless data flow between study planning, execution and monitoring — reducing silos and boosting efficiency.
“Our partnership with Viedoc brings together data management and clinical operational technologies that offer customers a choice of selecting the best-of-breed solutions for their clinical trials," noted Pharmaseal's CEO, Daljit Cheema.
"By integrating these complementary technologies, both process and data interoperability is increased — which improves the overall execution of clinical trials," he added.
“We’re pleased to welcome PHARMASEAL to Viedoc Verified, our official partner programme recognising trusted collaborators in clinical trial technology,” said Bob Egner, CPO at Viedoc.
“Our customers are seeking greater interoperability across their clinical systems to streamline operations and improve outcomes, and our collaboration with PHARMASEAL directly supports that need."
"By offering a truly connected eClinical experience through seamless integration of CTMS and EDC, we commit to empower sponsors, CROs and sites to get the most out of their clinical trials," he concluded.
